<p> <b>Full Title</b><br> Protocol HQP1351CG301: A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia </p> <p> <b>Study Treatment</b><br> Third-generation BCR-ABL1 tyrosine kinase inhibitor Olverembatinib vs bosutinib </p> <p> <b>Eligibility/Info</b><br> Eligible patient must have chronic phase chronic myeloid leukemia without a history of accelerated or blastic phase. <br> Part A: Treatment with at least two prior TKIs and confirmed absence of T315I and V229L mutations<br> Part B: Confirmed presence of T315I mutation, prior treatment with at least 1 TKI, and lack of other effective/tolerable therapies </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p>